Please select the option that best describes you:

Do you cycle through topical steroids in patients with CHE, and should the approval of delgocitinib change our approach on this?  



Answer from: at Academic Institution
Sign In or Register to read more

Answer from: at Community Practice
Sign In or Register to read more